Active Pharmaceutical Ingredient

Lificiguat API Manufacturer & Supplier in India | MEDIOCON INC

CAS: 170632-47-0 GMP Certified Aurangabad, Maharashtra, India
Lificiguat API Manufacturer & Supplier in India | MEDIOCON INC — Mediocon Inc
Lificiguat API Manufacturer & Supplier in India | MEDIOCON INC

Product Overview

CAS No: 170632-47-0

Lificiguat API is a synthetic small-molecule compound belonging to the indazole class and is also known by the research designation YC-1. Lificiguat has been investigated primarily as an activator of soluble guanylate cyclase (sGC) and as a pharmacological research compound with vasodilatory and platelet-aggregation-inhibitory properties.

Chemically, Lificiguat is identified as [5-(1-benzylindazol-3-yl)furan-2-yl]methanol. It contains an indazole nucleus substituted with a benzyl group and a hydroxymethyl-furan moiety. The compound has the molecular formula C₁₉H₁₆N₂O₂ and molecular weight approximately 304.3 g/mol. Its primary CAS number is 170632-47-0.

Lificiguat has been studied for its ability to activate soluble guanylate cyclase and influence the NO–cGMP signaling pathway. Experimental research has investigated its effects on vascular signaling, platelet aggregation, apoptosis and cellular responses associated with hypoxia-inducible pathways. PubChem describes Lificiguat as having roles including soluble guanylate cyclase activation, vasodilation, platelet aggregation inhibition and antineoplastic research.

The compound has also been investigated in cancer research and cellular pharmacology, including studies examining its effects on hypoxia-related signaling and tumor-cell responses. NCI's CellMiner database lists Lificiguat/YC-1 as a research compound and associates it with HIF1, HYP and EPAS1 mechanisms.

MEDIOCON INC supplies Lificiguat for applicable pharmaceutical research, medicinal chemistry, analytical research, vascular pharmacology studies and formulation-development requirements, subject to product availability, applicable regulatory requirements and supporting documentation.

Key Applications

  • Soluble guanylate cyclase research
  • Vascular pharmacology research
  • Platelet aggregation research
  • NO–cGMP pathway research
  • Hypoxia signaling research
  • Cancer research
  • Pharmaceutical R&D
  • Medicinal chemistry
  • Analytical research

Product Specifications

Product NameLificiguat API Manufacturer & Supplier in India | MEDIOCON INC
CAS Number170632-47-0

Sourcing, Regulatory & Export Information

Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Lificiguat API Manufacturer & Supplier in India | MEDIOCON INC (CAS 170632-47-0) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.

Our Lificiguat API Manufacturer & Supplier in India | MEDIOCON INC is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.

Export Markets

  • USA — FDA-registered facility; DMF support available for ANDA/NDA filings
  • Europe — EMA-compliant documentation; CEP/EDMF support on request
  • Africa & Middle East — WHO-GMP certified; competitive pricing for emerging markets
  • Southeast Asia — established logistics network; temperature-controlled shipments
  • India domestic — schedule H/X compliance; all state licensing documentation provided

Quality & Compliance

  • ISO 9001:2015 certified quality management system
  • GMP-certified manufacturing facility, Aurangabad, Maharashtra
  • Full batch traceability from raw material to finished API
  • Dedicated QA team for customer audits and regulatory queries

Frequently Asked Questions — Lificiguat API Manufacturer & Supplier in India | MEDIOCON INC

What is Lificiguat?
Lificiguat is a synthetic indazole derivative, also known as YC-1, investigated primarily as a soluble guanylate cyclase activator
💬
Mediocon AI
Hello 👋 How can I help you today?